We are live on ! Find out more
HARP

Harpoon Therapeutics, Inc. Common Stock
HARP

Delisted

HARP was delisted on the 8th of March, 2024.

Back to rankings

46 hedge funds and large institutions have $12.9M invested in Harpoon Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,030% more call options, than puts

Call options by funds: $313K | Put options by funds: $10K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

6% less capital invested

Capital invested by funds: $13.7M → $12.9M (-$767K)

6% less funds holding

Funds holding: 49 → 46 (-3)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

Holders
46
Holders Change
-3
Holders Change %
-6.12%
% of All Funds
0.73%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
10
Increased
11
Reduced
9
Closed
12
Calls
$313K
Puts
$10K
Net Calls
+$303K
Net Calls Change
+$281K

Top Buyers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
+$310K
2
LPC
Lion Point Capital
New York
+$142K
3
B
Bailard
California
+$53.1K
4
Two Sigma Investments
Two Sigma Investments
New York
+$48K
5
CWA
CM Wealth Advisors
Ohio
+$42.3K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$753K
2
Millennium Management
Millennium Management
New York
-$491K
3
LCS
Levin Capital Strategies
New York
-$239K
4
BlackRock
BlackRock
New York
-$130K
5
Renaissance Technologies
Renaissance Technologies
New York
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
MB
1
MPM BioImpact
Massachusetts
$2.38M – – –
NLVP
2
New Leaf Venture Partners
New York
$2.34M – – –
MAM
3
MPM Asset Management
Massachusetts
$2.33M – – –
Franklin Resources
4
Franklin Resources
California
$985K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$858K – – –
AG
6
Artal Group
Luxembourg
$744K – – –
Millennium Management
7
Millennium Management
New York
$486K -$491K -58,347 -47%
O
8
OrbiMed
New York
$462K -$753K -89,528 -59%
CAM
9
Cormorant Asset Management
Massachusetts
$402K – – –
KCM
10
Kennedy Capital Management
Missouri
$394K +$310K +36,844 +228%
BlackRock
11
BlackRock
New York
$318K -$130K -15,413 -27%
TCM
12
Tekla Capital Management
Massachusetts
$193K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$161K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$146K -$115K -13,655 -41%
LPC
15
Lion Point Capital
New York
$126K +$142K +16,928 New
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$84K -$11.1K -1,325 -10%
SFA
17
Sequoia Financial Advisors
Ohio
$74.4K +$33.6K +4,000 +67%
BCM
18
Bridgeway Capital Management
Texas
$74.4K +$42K +5,000 +100%
State Street
19
State Street
Massachusetts
$63.4K – – –
B
20
Bailard
California
$47K +$53.1K +6,320 New
Two Sigma Investments
21
Two Sigma Investments
New York
$42.5K +$48K +5,708 New
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$40.1K +$28.4K +3,383 +168%
Northern Trust
23
Northern Trust
Illinois
$39.4K -$34 -4 -0.1%
Prudential Financial
24
Prudential Financial
New Jersey
$32.3K +$36.5K +4,340 New
CWA
25
CM Wealth Advisors
Ohio
$29K +$42.3K +5,035 New
1
2 3

HARP Hedge Fund Activity: Q1 2023 in Review

46 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q1 2023, worth a combined $12.9M — down 5.6% from $13.7M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of HARP and 10 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.

The largest buyer was Kennedy Capital Management, adding an estimated $310K. The largest seller was OrbiMed, cutting an estimated $753K.

  • 46 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q1 2023, down from 49 in Q4 2022.
  • Funds reported $12.9M of Harpoon Therapeutics, Inc. Common Stock stock for Q1 2023, down 5.6% quarter-over-quarter.
  • 10 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q1 2023 and 12 closed out, a net change of -2 holders.
  • The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q1 2023 was Kennedy Capital Management, an estimated $310K added.
  • The largest Harpoon Therapeutics, Inc. Common Stock seller in Q1 2023 was OrbiMed, an estimated $753K sold.

Based on aggregated 13F filings for Q1 2023.